… benefit from clopidogrel treatment as compared with placebo than did noncarriers (rate of
primary outcome among carriers… The effect of clopidogrel on bleeding did not vary according to …

… In totality, we were able to examine the association of CYP2C19 genotype and clinical
outcomes in 9685 patients who initiated guideline-recommended treatment with clopidogrel, …

… -analyses on CYP2C19 genotype-guided antiplatelet therapy with clinical outcomes data …
interpretation of clinical CYP2C19 genotype test results to guide clopidogrel prescribing. As …

… linking CYP2C19 genotype with clinical outcomes among … know their CYP2C19 genotype
status at the time of treatment, and … management for those in whom genotype is available or for …

… effect-modification placebo-controlled trials included in this meta-analysis, there was no
evidence of a clopidogrel treatment × CYP2C19 genotype … risk of cardiovascular outcomes in the …

… loss-of-function allele carriers and poorer outcomes when treated with clopidogrel as … PCI,
where CYP2C19 genotype was assessed and included in the outcomes, and clopidogrel was …

… The purpose of these guidelines is to provide information regarding the clinical use of
CYP2C19 genotype test results in patients requiring antiplatelet therapy. Detailed guidelines for …

… Clopidogrel indication and ethnic population have been proposed to influence the effect
of CYP2C19 genotype. Methods and Results— …

… of clopidogrel, there was no effect of CYP2C19 genotype during ticagrelor therapy. …
Our results are consistent with the findings of the genetic substudy of the PLATO trial, where …

… The aim of this study was to examine the effect of CYP2C19 genotype on clinical outcomes
in … intervention (PCI), comparing those treated with ticagrelor or prasugrel versus clopidogrel. …